Bridgewater, NJ (USA), January 4, 2018 – Amneal Biosciences has launched busulfan injection, the company’s AP-rated therapeutic equivalent for Busulfex® 60 mg/10 mL (6 mg/1 mL). The product is supplied in cartons of eight single-dose vials, each containing 60 mg of busulfan in 10 mL of clear sterile solution. It is made without natural rubber latex, gluten or preservatives.

Busulfan injection is now shipping to wholesalers, distributors and direct to the trade.

Annual U.S. sales of Busulfex® were $80 million, according to October 2017 IQVIA™ market data.

About Amneal
Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC, is dedicated to the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics, anti-infectives and support care for healthcare providers and patients of all ages. The company’s expertise and focus on the unique needs and logistics of this market ensure the same level of quality and service for healthcare institutions and professionals that Amneal delivers to its retail customers.

Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high-quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit

All trademarks listed in this release are property of their respective owners.



John Niemi
Vice President, Sales
Amneal Biosciences

Business Development:
Apurva Saraf
Vice President,
Global Strategy & Corporate Development
Amneal Pharmaceuticals

Cheryl Lechok